New hope for tough brain tumors: experimental drug JZP3507 enters trial
NCT ID NCT07533942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called JZP3507 (ONC206) in 30 adults with recurrent grade 2 or 3 meningioma, a type of brain tumor. Participants take the drug three days a week in 28-day cycles. The main goal is to see if the drug can shrink tumors, with safety and response duration also tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JZP3507 (also called ONC206), an oral drug
What this could lead to
If successful, this could offer a new treatment option for people with recurrent meningioma who have run out of standard therapies.
What could go wrong
This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Louisiana State University
New Orleans, Louisiana, 70112, United States
-
Mass General
Boston, Massachusetts, 02114, United States
-
NYU- Langone Health
New York, New York, 10016, United States
-
Sutter Health
San Francisco, California, 94109, United States
-
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States